Truemeds, a Mumbai-based e-pharmacy and telehealth platform, has raised $85 million in its Series C funding round. The funding was completed in two tranches, the first led by Accel and the second by Peak XV Partners, with continued backing from WestBridge Capital and Info Edge Ventures.
The fresh funds raised will be used to open more fulfilment centers in non-metro areas, expand its engineering and product teams, and set up a new office in Bengaluru. It aims to triple its national penetration.
Founded in 2019 by Akshat Nayyar and Dr. Kunal Wani, Truemeds is closing the critical affordability gap in chronic care by offering high-quality alternatives to essential medicines, helping patients save 50–70% on their monthly bills. The platform primarily serves chronic care patients, including those managing diabetes, hypertension, and cardiovascular diseases.
Akshat Nayyar, Co-founder and CEO of Truemeds, said, “Our vision is simple- to bring the lowest prices for medicines in India, while ensuring every patient gets the quality they can trust. With this funding, we’re ready to strengthen our foundation, grow our offerings, and reach deeper into India’s non-metro regions, where access to affordable healthcare can truly change lives. We’re building a future where managing long-term health feels easier, more accessible, and never a compromise on care.”
Abhinav Chaturvedi, Partner at Accel, said, “India’s healthcare market is undergoing rapid transformation, yet affordability continues to be a major barrier—especially in chronic care. Truemeds is bridging this gap with a clinically guided, technology-led platform that delivers transparency and accessibility at scale. We’re excited to partner with Akshat, Kunal, and the team as they deepen access to affordable chronic care across the country.”
Sakshi Chopra, MD, Peak XV, said, “We are thrilled to partner with Akshat and Kunal at Truemeds as they build India’s most trusted e-pharmacy and healthcare platform. Their mission to make chronic care affordable for millions, especially in underserved non-metro markets, is both timely and transformative. By leveraging technology to deliver a seamless customer experience, they are redefining how essential medicines reach those who need them the most.”
